In vitro experiments highlighted PCBP2's potential as a diagnostic biomarker and immunotherapy target by inhibiting the cGAS-STING pathway, underscoring the importance of immune evasion in PCa and provides new opportunities for personalized immunotherapy. Here, CGAS is linked to posterior cortical atrophy.